| Validation Cohort | |||
---|---|---|---|---|
 | All patients | Non squamous | ||
Characteristic | HR (95% CI) | p value* | HR (95% CI) | p value* |
Age | 1.02 (1-1.04) | 0.02 | 1.03 (1-1.06) | 0.04 |
Gender | Â | Â | Â | Â |
Female | 1 | Â | Â | Â |
Male | 0.72 (0.44-1.18) | 0.19 | 0.6 (0.29-1.24) | 0.17 |
Stage | Â | Â | Â | Â |
Stage I | 1 | Â | 1 | Â |
Stage II | 1.9 (1.18-3) | 0.008 | 2.2 (1.07-4.54) | 0.03 |
Stage III | 3 (1.9-4.6) | < 0.001 | 3.6 (1.8-7.1) | < 0.001 |
Stage IV | 4.1 (2.4-7.02) | < 0.001 | 5.1 (2.5-10.49) | < 0.001 |
Histology | Â | Â | Â | Â |
Adenocarcinoma | 1 | Â | Â | Â |
Squamous cell carcinoma | 1.1 (0.76-1.6) | 0.6 | Â | Â |
Large cell carcinoma | 0.8 (0.19-3.46) | 0.8 | Â | Â |
Adenosquamous carcinoma | 0.9 (0.21-3.77) | 0.9 | Â | Â |
Giant cell carcinoma | 1.05 (0.46-2.41) | 0.9 | Â | Â |
Various | 1.5 (0.6-3.97) | 0.4 | Â | Â |
Differentiation | Â | Â | Â | Â |
High | 1 | Â | 1 | Â |
Moderate | 2.1 (0.99-4.6) | 0.05 | 3.01 (1.14-7.89) | 0.025 |
Low | 1.4 (0.67-3.03) | 0.3 | 1.38 (0.52-3.67) | 0.5 |
Bcl-2 | Â | Â | Â | Â |
Low | 1 | Â | 1 | Â |
High | 0.53 (0.37-0.75) | 0.0003 | 0.5 (0.31-0.81) | 0.005 |